At BIO-Europe 2024, Caszyme and Integra Therapeutics announced an exciting licensing deal for Cas12l nucleases. Caszyme’s CEO, Monika Paule, and Integra’s CEO, Avencia Sánchez-Mejías, discussed the details and significance of this collaboration on Biotech TV.
Watch the full interview here: https://www.biotechtv.com/post/integra-therapeutics-caszyme-november-4-2024